<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033925</url>
  </required_header>
  <id_info>
    <org_study_id>UKFC-PU-2019-01-08</org_study_id>
    <secondary_id>PRJ-82/LPDP/2019</secondary_id>
    <nct_id>NCT05033925</nct_id>
  </id_info>
  <brief_title>Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients</brief_title>
  <official_title>Safety and Clinical Efficacy Evaluation of Awar-awar Leaves (Ficus Septica Burm. F.) Active Fraction Capsule as Chemotherapy Complement in Stage IV Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gadjah Mada University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ahmad Dahlan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Kariadi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PT Konimex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LPDP, Kementerian Keuangan, Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gadjah Mada University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess the safety profile and clinical benefit of&#xD;
      Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study uses a double blind design and randomized controlled trial that compares the safety&#xD;
      and clinical efficacy profiles of 3 treatment groups (each consists of 97 subjects who&#xD;
      received chemotherapy for 6 cycles). The treatment group was given FADA at a dose of 800&#xD;
      mg/day and 2000 mg/day compared to the placebo group. Interim analysis is carried out after&#xD;
      25% of the subjects completed 3 cycles of chemotherapy; whereas interim analysis II is&#xD;
      carried out after 50% of the subjects completed 3 cycles of chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind; Randomized Controlled Trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>The measurement is at 3-7 days before the 4th cycle of chemotherapy (each cycle is 21 days), and 14-21 days after the 6th cycle (each cycle is 21 days)</time_frame>
    <description>The change of quality of life index during 6 cycles of chemotherapy (each cycle is 21 days). The score ranges from 0 (best) to 100 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>throughout the duration of the trial (126 days) or 6 cycles of chemotherapy (each cycle is 21 days)</time_frame>
    <description>Safety data will be collected by monitoring and recording all adverse events (AEs) and Serious Adverse Events(SAEs)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Breast Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receive a plasebo capsule 2 doses per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FADA 800 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive FADA capsules twice a day (each 400 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FADA 2000 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive FADA capsules twice a day (each 1000 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FADA (active fraction of Ficus septica leaf) 800 mg/day</intervention_name>
    <description>FADA is given twice a day (total dose of 800 per day per patient)</description>
    <arm_group_label>FADA 800 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FADA (active fraction of Ficus septica leaf) 2000 mg/day</intervention_name>
    <description>FADA is given twice a day (total dose of 2000 per day per patient)</description>
    <arm_group_label>FADA 2000 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsule is given twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, at least 18 years old&#xD;
&#xD;
          -  Welfare scale 0, 1, and 2 (ECOG - WHO)&#xD;
&#xD;
          -  Patients with stage IV breast cancer who have histopathological data according to the&#xD;
             TNM Classification of Malignant Tumors (TNM) from American Joint Committee on Cancer&#xD;
             (AJCC) 8th edition 2017&#xD;
&#xD;
          -  Patients who are willing to participate in the test and sign an informed consent&#xD;
&#xD;
          -  Patients who undergo breast cancer chemotherapy with luminal B sub-type or triple&#xD;
             negative with anthracycline base&#xD;
&#xD;
          -  Patients who are willing and able to fill out a questionnaire&#xD;
&#xD;
          -  The patients who are willing and able to comply with the test protocols during the&#xD;
             test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to meet the test protocol&#xD;
&#xD;
          -  Patients with liver and kidney disorders&#xD;
&#xD;
          -  Patients with other diseases/disorders that are meaningful according to the&#xD;
             investigators will be excluded from the test&#xD;
&#xD;
          -  Patients with cancer that has metastasized to the brain&#xD;
&#xD;
          -  Pregnant women and breastfeeding mothers&#xD;
&#xD;
          -  Patients with the ejection fraction smaller-than or equal to 55%&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>dr. Santosa, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Kariadi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nanang Fakhrudin, Ph.D</last_name>
    <phone>+62 85878502778</phone>
    <email>nanangf@ugm.ac.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Kariadi General Hospital</name>
      <address>
        <city>Semarang</city>
        <state>Jawa Tengah</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Anthony Suryo Purnomo</last_name>
      <phone>+62 8122650084</phone>
      <email>anthonysp@konimex.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gadjah Mada University</investigator_affiliation>
    <investigator_full_name>Nanang Fakhrudin</investigator_full_name>
    <investigator_title>Head of Department of Pharmaceutical Biology, Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>ficus septica</keyword>
  <keyword>cancer</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

